Pharmaceutical composition for treating and/or preventing ovarian cancer, and preparation method and application thereof

Abstract

The invention provides a pharmaceutical composition for treating and / or preventing ovarian cancer. Active ingredients of the composition comprise cis-platinum and alectinib, and the weight ratio of cis-platinum to alectinib is (1:50)-(50:1). According to the invention, the ratio of cis-platinum to alectinib in the pharmaceutical composition is scientifically screened, and different anti-cancer principles and interactions of the two medicines are fully utilized. The two medicines generate a remarkable synergistic effect when being used for treating ovarian cancer, and the treatment effect of the ovarian cancer is greatly improved. Icariin is added, and the dosage of icariin is reasonably screened, so that firstly, the body weakness symptom of a patient is improved and the anti-cancer effectis improved by adjusting an immune system; secondly, the medicine dosage is reduced, and the medicine taking compliance of a patient is improved; thirdly, medical cost and expense burden of a patientare reduced; and fourthly, the three active ingredients supplement each other internally and externally, so that the anticancer effect is comprehensively exerted, the toxic and side effects of chemotherapy are reduced, the life cycle of a patient is prolonged, and the life quality of the patient is improved.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to a pharmaceutical composition for treating and / or preventing ovarian cancer, a preparation method and application thereof. Background technique [0002] Ovarian cancer is one of the three major malignant tumors of female genitalia, but its mortality rate ranks first among gynecological malignant tumors. In recent years, the incidence of ovarian cancer has increased year by year. The early symptoms of ovarian cancer are hidden, and abdominal metastasis often occurs before the symptoms appear. 60%-70% of the patients are already in the advanced stage when they go to the doctor. The initial treatment of ovarian cancer is mainly surgery, supplemented by chemotherapy, combined with radiotherapy and biological treatment. Although complete remission can be achieved after initial surgery and chemotherapy, most patients with advanced disease will relapse within 2-3 years, and eventually become...

AI Technical Summary

Problems solved by technology

[0004] First, the curative effect is not ideal

There are differences in the biological characteristics of tumor cells among different individuals, and the sensitivity to chemotherapy drugs varies, resulting in great uncertainty in the treatment efficiency of cisplatin

In order to obtain a stable curative effect, it is usually necessary to precisely control the dosage, which not only requires a high level of medical personnel's operation, but also has a large medical risk

[0005] Second, the side effects

Cisplatin is prone to severe adverse reactions such as nausea, vomiting, renal tubular damage, tinnitus caused by nerve damage, and hearing loss during the use of cisplatin, which not only seriously affects the treatment compliance of ovarian cancer patients, but also leads to severe vomiting and poor appetite. Insufficient intake, the patient's blood is mostly in a hypercoagulable state, which increases the risk of distant metastasis of cancer cells

[0006] Third, the applicable population is limited

[0007] Fourth, the cost of treatment is high, and the cost of cisplatin treatment is relatively high. Restricted by economic conditions, the degree of patient cooperation with treatment is poor, and some patients' families cannot bear the economic pressure and give up treatment.

Images